ESC 365 - Impact of vericiguat use in real life. New insight of the VERITA registry.

Open Access

Impact of vericiguat use in real life. New insight of the VERITA registry.

Session: Novel insights into heart failure therapeutics

Topic: Pharmacotherapy

Speaker: Doctor M. Groba Marco (Las Palmas de Gran Canaria, ES)

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Doctor Maria Del Val Groba Marco

Las Palmas de Gran Canaria University, Las Palmas de Gran Canaria (Spain)

0 follower

6 more presentations in this session

Clinical presentation and treatment landscape of patients with transthyretin amyloidosis with cardiomyopathy: a real-world study in five European countries and Japan

Speaker: Doctor C. Morbach (Wuerzburg, DE)

Start as we mean to go on - when aggression is the answer, assessing the impact of setting of heart failure diagnosis on number of pillars at optimisation

Speaker: Doctor N. Melarkey (Newry, GB)

Comparison of dapagliflozin 10 mg versus empagliflozin 10 mg in heart failure patients without type 2 diabetes mellitus on top of triple guideline-directed medical therapy

Speaker: Associate Professor I. Colluoglu (Karabuk, TR)

Tricuspid regurgitation is a barrier to guideline-directed medical therapy implementation in patients with acute decompensated heart failure and reduced ejection fraction

Speaker: Doctor D. Cocianni (Trieste, IT)

Frailty is associated with suboptimal guideline-directed medical therapy in heart failure hospital admissions

Speaker: Mr A. Maggi (Brescia, IT)

Access the full session

Novel insights into heart failure therapeutics

Speakers: Doctor M. Groba Marco, Doctor C. Morbach, Doctor N. Melarkey, Associate Professor I. Colluoglu, Doctor D. Cocianni...

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources